Search alternatives:
estimates decrease » estimates decreased (Expand Search), estimated release (Expand Search)
significant effect » significant impact (Expand Search)
effect decrease » effects decreased (Expand Search)
Showing 161 - 180 results of 44,070 for search '(( significant ((estimates decrease) OR (estimated decrease)) ) OR ( significant effect decrease ))', query time: 0.94s Refine Results
  1. 161
    Estimated annual variation in predicted skin lesion point prevalence by pod.

    Estimated annual variation in predicted skin lesion point prevalence by pod. by Joseph K. Gaydos (8830838)

    Published 2023
    Save to List
    Saved in:
  2. 162
    Top pathways detected by the enrichment analysis of the hub-genes whose degree decreased from IL and PL to LHB.

    Top pathways detected by the enrichment analysis of the hub-genes whose degree decreased from IL and PL to LHB. by Souvik Seal (12437166)

    Published 2023
    Save to List
    Saved in:
  3. 163
    5-fluorouracil decreases rates of persistent and reappearing actinic keratoses: The VAKCC Trial

    5-fluorouracil decreases rates of persistent and reappearing actinic keratoses: The VAKCC Trial by Moniyka Sachar (9399032)

    Published 2020
    Save to List
    Saved in:
  4. 164
    Estimated power losses of different main components used in this converter.

    Estimated power losses of different main components used in this converter. by M. Zakir Hossain (6033752)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 165
    Bivariate regression results estimating stigma endorsement against PLHIV.

    Bivariate regression results estimating stigma endorsement against PLHIV. by Sulemana Ansumah Saaka (17817434)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 166
    Multiple regression results estimating stigma endorsement against PLHIV.

    Multiple regression results estimating stigma endorsement against PLHIV. by Sulemana Ansumah Saaka (17817434)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 167
    No effects of tDCS on the attentional blink at the group level.

    No effects of tDCS on the attentional blink at the group level. by Leon C. Reteig (5713010)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  8. 168
    Path model estimating direct and indirect effects of impulsivity on self-care outcomes among individuals diagnosed with prediabetes, controlling for BMI.

    Path model estimating direct and indirect effects of impulsivity on self-care outcomes among individuals diagnosed with prediabetes, controlling for BMI. by Katherine Wainwright (8359272)

    Published 2022
    Save to List
    Saved in:
  9. 169
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 170
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 171
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 172
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 173
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 174
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 175
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 176
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 177
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 178
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 179
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 180
    Input parameters for the base-case analysis.

    Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: